MARKET OVERVIEW:

The global gastric cancer drugs market is witnessing rapid growth, driven by the increasing prevalence of gastric cancer and advancements in drug development. Valued at USD 5.2 billion in 2024, the market is projected to reach USD 13.5 billion by 2033, growing at a CAGR of 10.7% from 2025 to 2033. Factors such as an aging population, rising obesity rates, and the development of targeted therapies are pivotal in fueling this market's expansion.

STUDY ASSUMPTION YEARS:

• BASE YEAR: 2024
• HISTORICAL YEAR: 2019-2024
• FORECAST YEAR: 2025-2033

GASTRIC CANCER DRUGS MARKET KEY TAKEAWAYS:

• The gastric cancer drugs market was valued at USD 5.2 billion in 2024 and is expected to grow to USD 13.5 billion by 2033, at a CAGR of 10.7%.
• Trastuzumab holds the largest market share due to its effectiveness in treating HER2-positive gastric cancer.
• The market is experiencing technological breakthroughs, particularly in immunotherapy and biosimilars.
• Asia Pacific dominates the market due to higher gastric cancer prevalence.
• Hospitals remain the primary end users for gastric cancer drugs.
• Increasing focus on biosimilars and immunotherapy is expected to drive future market growth.

MARKET GROWTH FACTORS:

Technological Advancements:

The advanced treatment developments, especially in biosimilars and immunotherapies such as immune checkpoint inhibitors, are seen adding a significant part to the market growth. This however, is mainly brought about by biosimilars, as they are the most cost-effective option in making cancer medicines more widely available across the globe. Immunotherapy would improve the survival payments even in late stages of gastric cancer, making them very essential as a role in the extension of the market.

Increasing Disease Prevalence and Risk Factors:

There are two populations factors that made great contributions to the market: globally rising obesity and increasing age. It was revealed that gastric cancer has higher risks with obesity that demand treatments; the part that also involves increased incidence rates comes from regions in Asia, which exhibit high infection incidences of Helicobacter pylori.

Regulatory Impact and Market Demand:

The rising demand for treatment is fueled by increasing awareness about gastric cancer and growing health consciousness worldwide. To reduce costs and improve affordability, several governments have partnered with pharmaceutical companies. The combination of this regulatory support along with localized clinical trials is expected to provide substantial opportunity for the gas solid market for gastric cancer drugs.

MARKET SEGMENTATION:

• By Type:
  • Doxorubicin Hydrochloride: An anthracycline antibiotic used in chemotherapy.
  • Sunitinib: A tyrosine kinase inhibitor for advanced gastric cancer treatment.
  • Docetaxel: A chemotherapy drug commonly used in gastric cancer treatment.
  • Mitomycin: An alkylating agent for various cancers, including gastric cancer.
  • Fluorouracil: A chemotherapy medication that interferes with DNA replication.
  • Imatinib: A targeted therapy drug for gastric cancer with specific molecular targets.
  • Trastuzumab: A monoclonal antibody used for HER2-positive gastric cancer treatment.
• By Route of Administration:
  • Oral: Drugs administered through oral ingestion.
  • Parenteral: Intravenous or subcutaneous administration, often used in advanced stages for quicker drug absorption.
• By End-User:
  • Hospitals: The largest segment, where most treatments are provided.
  • Clinics: Smaller-scale treatment facilities focused on specific patient groups.
  • Others: Other healthcare settings involved in gastric cancer drug administration.
• Breakup by Region:
  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

REGIONAL INSIGHTS:

The gastric cancer drugs market is largely driven by the regions of Asia Pacific owing to the high prevalence of gastric cancer in countries like Japan, China, and South Korea. Diet, contact with pets infected with H. Pylori, and high aging contribute to this increase in the population. Increased demand for effective treatments is projected to keep Asia Pacific as a leading follower.

RECENT DEVELOPMENTS & NEWS:

New approvals of trastuzumab biosimilars lead the market towards expansion since they have been able to achieve lower treatment costs. Recently, a few advances in immunotherapy, such as that spearheaded by BeiGene's PD-1 cancer drug Tevimbra, have highlighted good action alternatives to the traditional norm of chemotherapy. Increased localized clinical trials, such as zolbetuximab studies, have increased treatment for gastric cancer.

KEY PLAYERS:

• Abbott Laboratories
• Arog Pharamaceuticals Inc.
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Ono Pharmaceutical Co. Ltd.
• Sanofi S.A.
• Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization. 

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.